LC-MS based metabolomics identification of novel biomarkers of tobacco smoke-induced chronic bronchitis

Biomedical Chromatography

Volumn 30, Issue 1, 2016, Pages 68-74

  Ren, Xiaolei ^a   Zhang, Jiayu ^a   Fu, Xiaorui ^a   Ma, Shuangshuang ^a   Wang, Chunguo ^a   Wang, Juan ^a   Tian, Simin ^a   Liu, Siqi ^a   Zhao, Baosheng ^a   Wang, Xueyong ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Chronic bronchitis; LC MS; Lysophosphatidylethanolamine; Metabolomics; Tobacco smoke

Indexed keywords

BODY FLUIDS; FATTY ACIDS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PHOSPHOLIPIDS; PHYSIOLOGY; RATS; SMOKE; TOBACCO;

CAUSATIVE AGENTS; CHRONIC BRONCHITIS; EXPOSED TO; LIPID METABOLISMS; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES; LYSOPHOSPHATIDYLETHANOLAMINE; METABOLIC PROFILING; METABOLOMICS; NON-TARGETED; TOBACCO SMOKE;

BIOMARKERS;

12 HYDROXYICOSATETRAENOIC ACID; 4 IMIDAZOLONE 5 PROPIONIC ACID; 5 HYDROXYINDOLEACETIC ACID; 5' CARBOXY GAMMA TOCOPHEROL; AMINO ACID; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; LIPID; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLETHANOLAMINE (18 0); LYSOPHOSPHATIDYLETHANOLAMINE (18 1); LYSOPHOSPHATIDYLETHANOLAMINE (20 4); LYSOPHOSPHATIDYLETHANOLAMINE(16 0); TOBACCO SMOKE; UNCLASSIFIED DRUG; URIDINE; LYSOPHOSPHATIDYLETHANOLAMINE; LYSOPHOSPHOLIPID; SMOKE;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC BRONCHITIS; CONTROLLED STUDY; HISTOPATHOLOGY; INFLAMMATION; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; RAT; SERUM; ADVERSE EFFECTS; ANIMAL; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; EVALUATION STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PROCEDURES; SMOKE; SPRAGUE DAWLEY RAT; TOBACCO;

ANIMALS; BIOMARKERS; BRONCHITIS, CHRONIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; MALE; MASS SPECTROMETRY; METABOLOMICS; RATS; RATS, SPRAGUE-DAWLEY; SMOKE; TOBACCO;

EID: 84952638593     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3620     Document Type: Article

References (45)

1. Abu El-Asrar AM, Nawaz MI, Mobammad G, Siddiquei MM, Alam K and Mousa A. Expression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathy. Lipids in Health and Disease 2014; 13: 187.
2. Agarwal S, Rokadia H, Senn T and Menon V. Burden of cardiovascular disease in chronic obstructive pulmonary disease. American Journal of Preventive Medicine 2014; 47: 105-114.
3. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J and Busquets X. Systemic effects of chronic obstructive pulmonary disease. European Respiratory Journal 2003; 21: 347-360.
4. Bahr TM, Hughes GJ, Armstrong M, Reisdorph R, Coldren CD, Edwards MG, Schnell C, Kedl R, LaFlanne DJ, Reisdorph N, Kechris KJ and Bowler RP. Peripheral blood mononuclear cell gene expression in chronic obstructive pulmonary disease. American Journal of Respiratory Cell and Molecular Biology 2013; 49: 316-323.
5. Bot M, de Jager SCA, MacAleese L, Lagraauw HM, Van Berkel TGC, Quax PHA, Kuiper J, Heeren RMA, Biessen EAL and Bot I. Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation. Journal of Lipid Research 2013; 54: 1265-1274.
6. Breault CD, Hathcock D, Beaver C, Cairns C and Kraft C. Metabolomic and inflammatory profiling in patients with chronic obstructive pulmonary disease (COPD). American Journal of Respiratory and Critical Care Medicine 2011; 183: A4107.
7. Chen J, Zhang XY, Cao R, Lu X, Zhao SM, Fekete A, Huang Q, Schmitt-Kopplin P, Wang YS and Xu ZL. Serum 27-nor-5 beta-cholestane-3, 7, 12, 24, 25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. Journal of Proteome Research 2011; 10: 2625-2632.
8. Chen LJ, Fan JJ, Li YB, Shi XL, Ju DW, Yan QL, Yan X, Han L and Zhu HY. Modified Jiu Wei Qiang Huo decoction improves dysfunctional metabolomics in influenza A pneumonia-infected mice. Biomedical Chromatography 2014; 28: 468-474.
9. Croset M and Lagarde M. Stereospecific inhibition of PGH2-induced platelet aggregation by lipoxygenase products of icosaenoic acids. Biochemical and Biophysical Research Communications 1983; 112: 878-883.
10. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA and Tal-Singer R. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respiratory Research 2011; 12: 146.
11. Eisner MD, Balmes J, Katz PP, Trupin L, Yelin EH and Blanc PD. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environmental Health 2005; 4: 7.
12. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Molecular Biology 2002; 48: 155-171.
13. Gross CP, Anderson GF and Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. New England Journal of Medicine 1999; 340: 1881-1887.
14. Hashimoto T, Yamashita M, Ohata H and Momose K. Lysophosphatidic acid enhances in vivo infiltration and activation of guinea pig eosinophils and neutrophils via a Rho/Rho-associated protein kinase-mediated pathway. Journal of Pharmacological Sciences 2003; 91: 8-14.
15. Houben AJS and Moolenaar WH. Autotaxin and LPA receptor signaling in cancer. Cancer and Metastasis Reviews 2011; 30: 557-565.
16. Huang Q, Tan YX, Yin PY, Ye GZ, Gao P, Lu X, Wang HY and Xu GW. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Research 2013; 73: 4994-5002.
17. Jin Y, Knudsen E, Wang L and Maghazachi AA. Lysophosphatidic acid induces human natural killer cell chemotaxis and intracellular calcium mobilization. European Journal of Immunology 2003; 33: 2083-2089.
18. Kim V and Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2014; 187: 228-237.
19. Knowlden S and Georas SN. The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. Journal of Immunology 2014; 192: 851-857.
20. Lindon JC, Holmes E and Nicholson JK. Metabonomics techniques and applications to pharmaceutical research & development. Pharmaceutical Research 2006; 23: 1075-1088.
21. Liu HY, Zhang L, Zhao BS, Zhang ZX, Qin LL, Zhang QQ, Wang Q, Lu ZW and Gao XY. Hypothalamus metabolomic profiling to elucidate the tissue-targeted biochemical basis of febrile response in yeast-induced pyrexia rats. Chemico-Biological Interactions 2015; 231: 61-70.
22. Maricic I, Girardi E, Zajonc DM and Kumar V. Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease. Journal of Immunology 2014; 193: 4580-4589.
23. Massaro M, Habib A, Lubrano L, Del Turco S, Lazzerini G, Bourcier T, Weksler BB and De Caterina R. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 15184-15189.
24. McClay JL, Adkins DE, Isern NG, O'Connell TM, Wooten JB, Zedler BK, Dasika MS, Webb BT, Robertson BJ and Pounds JG. H-1 nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function. Journal of Proteome Research 2010; 9: 3083-3090.
25. Morrow JD, Qiu WL, Chhabra D, Rennard SI, Belloni P, Belousoy A, Pillai SG and Hersh CP. Identifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methods. BMC Medical Genomics 2015; 8: 1.
26. Naz S, Vallejo M, García A and Barbas C. Method validation strategies involved in non-targeted metabolomics. Journal of Chromatography A 2014; 1353: 99-105.
27. Nicholson JK, Connelly J, Lindon JC and Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nature Reviews Drug Discovery 2002; 1: 153-161.
28. Nicholson JK, Wilson ID and Lindon JC. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 2011; 12: 103-111.
29. Okudaira S, Yukiura H and Aoki J. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 2010; 92: 698-706.
30. Oudijk EJD, Lammers JWJ and Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. European Respiratory Journal 2003; 46: 5s-13s.
31. Pelkonen M, Notkola IL, Nissinen A, Tukiainen H and Koskela H. Thirty year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006; 130: 1129-1137.
32. Peterson JW, Boldoqh I, Popov VL, Saini SS and Chopra AK. Anti-inflammatory and antisecretory potential of histidine in Salmonella-challenged mouse small intestine. Laboratory Investigation 1998; 78: 523-534.
33. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R and Celli B. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007; 62: 595-601.
34. Schober C, Schiller J, Pinker F, Hengstler JG and Fuchs B. Lysophosphatidylethanolamine is-in contrast to-choline-generated under in vivo conditions exclusively by phospholipase A2 but not by hypochlorous acid. Bioorganic Chemistry 2009; 37: 202-210.
35. Scholz M, Gatzek S, Sterling A, Fiehn O and Selbig J. Metabolite fingerprinting: detecting biological features by independent component analysis. Bioinformatics 2004; 20: 2447-2454.
36. Seki H, Fukunaga K, Arita M, Arai H, Nakanishi H, Taguchi R, Miyasho T, Takamiya R, Asano K and Ishizaka A. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. Journal of Immunology 2010; 184: 836-843.
37. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G and Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. Journal of Experimental Medicine 2002; 196: 1025-1037.
38. Teague SV, Pinkerton KE, Goldsmith M, Gebremichael A, Chang S, Jenkins RA and Moneyhun JH. Sidestream cigarette smoke generation and exposure system for environmental tobacco smoke studies. Inhalation Toxicology 1994; 6: 79-93.
39. Tomsig JL, Snyder AH, Berdyshev EV, Skobeleba A, Mataya C, Natarajan V, Brindley DN and Lynch KR. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochemical Journal 2009; 419: 611-618.
40. Vulimiri SV, Misra M, Hamm JT, Mitchell M and Berger A. Effects of mainstream cigarette smoke on the global metabolome of human lung epithelial cells. Chemical Research in Toxicology 2009; 22: 492-503.
41. 1H NMR based spectroscopy discriminates patients with chronic obstructive pulmonary disease and healthy individuals. Plos One 2013; 8: e65675.
42. Want EJ, Masson P, Michopoulos F, Wilson ID, Theodoridis G, Plumb RS, Shockcor J, Loftus N, Holmes E and Nicholson JK. Global metabolic profiling of animal and human tissues via UPLC-MS. Nature Protocols 2013; 8: 17-32.
43. Watanabe M, Suliman ME, Qureshi AR, Garcia-Lopez E, Bárány P, Heimbürger O, Stenvinkel P and Lindholm B. Consequences of low plasma histidine in chronic kidney disease patients: associations with inflammation, oxidative stress, and mortality. American Journal of Clinical Nutrition 2008; 6: 1860-1866.
44. Wolfender JL, Marti G, Thomas A and Bertrand S. Current approaches and challenges for the metabolite profiling of complex natural extracts. Journal of Chromatography A 2015; 1382: 136-164.
45. Yin PY, Zhao XJ, Li QR, Wang JS, Li JS and Xu GW. Metabonomics study of intestinal fistulas based on ultraperformance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC/Q-TOF MS). Journal of Proteome Research 2006; 5: 2135-2143.